Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biosimilar Product Development Meetings With FDA To Be Flexible Under User Fee Program

This article was originally published in The Pink Sheet Daily

Executive Summary

Agency says pre-marketing application meetings will not be mandatory; program independence issue also appears resolved.
Advertisement

Related Content

Biosimilar User Fee Program Stresses FDA/Sponsor Meetings Early And Often
Biosimilar Players Will Be Manufacturers Large And Small, Analyst Predicts
Biosimilar Players Will Be Manufacturers Large And Small, Analyst Predicts
Biosimilar User Fee Agreement Reached, But Will Require Appropriations Boost
Biosimilar User Fee Agreement Reached, But Will Require Appropriations Boost
ANDA User Fee Negotiations Finished; Backlog To Be Mostly Cleared By Year Five
Biosimilar User Fee Negotiations Hit Snag With GPhA Gambit For Lower Fees
Biosimilar User Fees Would Be Same As BLAs, Only Earlier
Biosimilar User Fees Would Be Same As BLAs, Only Earlier

Topics

Advertisement
UsernamePublicRestriction

Register

PS072772

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel